Scancell (LON:SCLP) Sets New 52-Week Low – Here’s Why

Scancell Holdings plc (LON:SCLP)’s stock price hit a new 52-week low during trading on Tuesday. The stock traded as low as GBX 79.80 and last traded at GBX 81, with a volume of 751,889 shares. The stock had previously closed at GBX 81.

Scancell Stock Performance

The stock has a market cap of £108.53 million, a P/E ratio of -4.62 and a beta of 0.69. The company has a debt-to-equity ratio of -88.01, a current ratio of 0.28 and a quick ratio of 13.01. The company has a fifty day moving average of GBX 92.99 and a 200 day moving average of GBX 131.23.

Scancell (LON:SCLP) last issued its quarterly earnings results on Friday, October 9th. The company reported GBX (17.30) earnings per share (EPS) for the quarter. Scancell had a negative net margin of 116.98% and a positive return on equity of 128.87%. On average, equities analysts predict that Scancell Holdings plc will post -2.54 earnings per share for the current fiscal year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.